A revolutionary drug , retatrutide, is generating considerable anticipation within the Oz weight management community. Developed by Eli Lilly , this dual GIP and GLP-1 receiver appears to provide more substantial outcomes than current therapies. Preliminary clinical studies have shown noteworthy